FDA 483 - Medtronic Neuromodulation - June 22, 2006

An FDA inspection of Medtronic Neurological in Minneapolis, MN, conducted from May to June 2006, revealed significant deficiencies in their quality system for medical devices. The observations, detailed in an FDA 483, primarily concerned the 8731 Intrathecal Catheter and Synchromed EL implantable infusion pumps, highlighting non-compliance with medical device quality system regulations. Key issues included inadequate design controls, specifically for the 8731 catheter, where design input requirements were not fully implemented, and validation testing was not conducted using production-equivalent units. Critical manufacturing processes, such as tip bonding, were not properly validated, and production processes lacked adequate control, including uncorrected procedural errors and undocumented equipment breakdowns. Furthermore, the company's corrective and preventive action (CAPA) system was found to be ineffective. Investigations into recurring product nonconformities, such as catheter tip dislodgements and pump motor stalls, were incomplete or based on unsubstantiated conclusions, and planned corrective actions, like product redesigns, were not fully implemented. Critical actions to address distributed susceptible products were also delayed or missing. Documentation issues extended to incomplete device history records and medical device reports lacking essential patient follow-up information. Medtronic Neurological is required to address these observations with comprehensive corrective and preventive actions to ensure the safety, effectiveness, and quality of its medical devices.